قلم مونجارو كويكبن 2.5 ملجم معبئ مسبقًا 0.6 مل

Mounjaro (tirzepatide) 2.5mg is the first and lowest dose prescribed for adults with type 2 diabetes to begin their treatment. This once-weekly injectable medicine is a dual GIP and GLP-1 receptor agonist, a unique class of drugs that works by helping your body naturally produce more insulin when blood sugar levels are high. It also reduces the amount of glucose produced by the liver and slows down digestion.

The 2.5mg dose is specifically intended for treatment initiation to help your body gradually adjust to the medication, which can reduce the risk of gastrointestinal side effects. It is not designed to be a long-term maintenance dose. After completing the first four weeks on the 2.5mg dosage, your doctor will likely increase your dose to 5mg, which is when the medication begins to exert its primary blood sugar-lowering effects.